Editorial Expression of Concern: Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells

Br J Cancer. 2024 Sep;131(5):955. doi: 10.1038/s41416-024-02813-5.

Authors

N Johnson^{1

2}, J Bentley¹, L-Z Wang¹, D R Newell¹, C N Robson¹, G I Shapiro², N J Curtin³

Affiliations

¹ Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK.
² Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA, 02115, USA.
³ Northern Institute for Cancer Research, Newcastle University, Paul O' Gorman Building, Framlington, Newcastle upon Tyne, NE2 4HH, UK. [email protected].

PMID: 39160248
PMCID: PMC11368910 (available on 2025-08-19)
DOI: 10.1038/s41416-024-02813-5

No abstract available

Publication types

Editorial
Expression of Concern

MeSH terms

Breast Neoplasms* / drug therapy
Breast Neoplasms* / genetics
Breast Neoplasms* / pathology
CDC2 Protein Kinase / genetics
CDC2 Protein Kinase / metabolism
Cell Line, Tumor
Drug Resistance, Neoplasm* / genetics
Estrogen Antagonists / pharmacology
Estrogen Antagonists / therapeutic use
Female
Humans
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use

Substances

CDC2 Protein Kinase
Protein Kinase Inhibitors
Estrogen Antagonists